Inhibition of Vincristine Binding in Drug-Resistant Cancer Cells
Author Information
Author(s): M. Sehested, P. Buhl Jensen, T. Skovsgaard, N. Bindslev, E.J.F. Demant, E. Friche, L. Vindeløv
Primary Institution: Herlev University Hospital and The Finsen Institute, Copenhagen, Denmark
Hypothesis
Does the inhibition of drug binding to the plasma membrane correlate with the ability of MDR modulators to enhance intracellular drug accumulation and inhibit drug efflux?
Conclusion
The study concludes that the ability of MDR modulators to reverse resistance to vincristine correlates with their capacity to increase intracellular drug levels rather than their ability to inhibit drug binding to the plasma membrane.
Supporting Evidence
- Vincristine binding to MDR cells was inhibited by quinidine, verapamil, and trifluoperazine.
- Trifluoperazine was the most effective modulator in raising intracellular vincristine levels.
- Tween 80 modulated resistance to vincristine at a concentration of 0.001%.
Takeaway
Some drugs can help cancer cells take in more medicine, making the medicine work better against the cancer. But just blocking the medicine from sticking to the cell's surface doesn't help.
Methodology
The study used plasma membrane vesicles from drug-resistant cancer cells to measure the binding of vincristine and the effects of various modulators on drug accumulation and efflux.
Limitations
The study does not address the long-term effects of these modulators on drug resistance or their potential toxicity in clinical settings.
Want to read the original?
Access the complete publication on the publisher's website